- Home
- SLS
as 12-18-2024 9:43am EST
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 75.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $1.72 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest SELLAS Life Sciences Group Inc. News
SLS Breaking Stock News: Dive into SLS Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
GlobeNewswire
9 days ago
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
Clinical Trials Arena
20 days ago
SELLAS announces data indicating key predictor of response to SLS009 in solid cancers
GlobeNewswire
21 days ago
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
Simply Wall St.
a month ago
We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate
GlobeNewswire
a month ago
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
MT Newswires
2 months ago
SELLAS Life Sciences Gets FDA Rare Pediatric Disease Designation for Acute Myeloid Leukemia Immunotherapy
Compare SLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLS SELLAS Life Sciences Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.